Paradigm Biopharmaceuticals

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on transforming underutilized molecules into effective treatments. By combining cutting-edge science and extensive experience, the company addresses significant unmet medical needs, offering hope to patients and opportunities to investors. Paradigm aims to reduce the time, cost, and risk of bringing new products to market.

Products & Services

Pentosan Polysulfate Sodium:A lead product targeting osteoarthritis (OA), Mucopolysaccharidosis VI (MPS VI), and Mucopolysaccharidosis I (MPS I), with a focus on safety profile, mechanism of action, and commercialization potential.

Osteoarthritis (OA) Treatment:A treatment under development for osteoarthritis, part of Paradigm's product pipeline.

MPS VI Treatment:A treatment under development for Mucopolysaccharidosis VI, addressing rare disease needs.

Specialties

Drug Development Repurposing Underutilized Molecules Osteoarthritis Treatment Rare Disease Treatments (MPS) Clinical Trials and Regulatory Expertise

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Securities Issuance T: - FT: Securities Issuance	A: 1708 MR: - FA: 1,708 FAN: 1708	D: 2025-07-22 FD: 2025-07-22	-

Securities Issuance Latest

2025-07-22

$2K

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Paul Rennie

Managing Director

LinkedIn (Pro only)

D

Donna Skerrett

Chief Medical Officer

LinkedIn (Pro only)

A

Amos Meltzer

Non-Executive Director

LinkedIn (Pro only)

M

Matthew Fry

Non-Executive Director

S

Samantha Williams

Director of Business Operations

K

Karla Knower

Regulatory Affairs

View 9 more team members with Pro

Unlock Full Team Directory

Recent News